Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | BTK | Q06187 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MITF | O75030 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.32 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4069963 | 0.81 | MCHR1 (0.39) | DYRK1ASMN1; SMN2HSD17B10ALDH1A1KMT2A | |
| SCHEMBL13495163 | 0.77 | LRRK2 (0.35) | SMN1; SMN2BTKKMT2ANOTUMMEN1 | |
| SCHEMBL4268521 | 0.77 | BTK (0.38) | SMN1; SMN2BTKKMT2ANOTUMMEN1 | |
| SCHEMBL28119869 | 0.77 | BTK (0.32) | BTKKMT2ANOTUMMAP4K4LRRK2 | |
| SCHEMBL161724 | 0.76 | — | — | |
| SCHEMBL31080659 | 0.75 | GAA (0.40) | DYRK1ASMN1; SMN2HSD17B10BTKALDH1A1 | |
| Hydrochloric Acid SCHEMBL219321 | 0.74 | — | — | |
| SCHEMBL30849109 | 0.71 | — | — | |
| SCHEMBL6962038 | 0.71 | DYRK1A (0.71) | DYRK1ASMN1; SMN2HSD17B10BTKALDH1A1 | |
| SCHEMBL19767664 | 0.71 | PTGS1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695238-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2026-02-18 | — | — | EP | disclosed |
| WO-2025080653-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINE COMPOUNDS ACTING AGAINST CANCERS, INFLAMMATORY DISEASES, AND FIBROTIC DISEASE VIA INTERACTION WITH RAS SUPERFAMILY PROTEINS | SHY THERAPEUTICS, LLC (US) | 2025-04-17 | — | — | WO | disclosed |
| WO-2024216154-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2024-10-17 | — | — | WO | disclosed |
| CN-116782883-A | Topical pharmaceutical compositions and methods | 金字塔生物科技公司 | 2023-09-19 | — | — | CN | disclosed |
| WO-2022144758-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS AND METHODS | PYRAMID BIOSCIENCES, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| WO-2022144758-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS AND METHODS | PYRAMID BIOSCIENCES, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| US-10738033-B2 | Trk inhibition | NANTBIO, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20180346451-A1 | TRK INHIBITION | NANTBIO, INC. | 2018-12-06 | — | — | US | disclosed |
| CN-104352492-B | Extend enzyme inhibitor using arylsulfonyl derivatives as the long chain fatty acids of active ingredient | MSD K.K.公司 | 2017-12-05 | — | — | CN | disclosed |
| EP-2236494-B1 | SULFONYL SUBSTITUTED 6-MEMBERED RING DERIVATIVE | MSD KK (JP) | 2016-08-31 | — | — | EP | disclosed |
| EP-1853602-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2007-11-14 | — | — | EP | disclosed |
| EP-1846394-A1 | PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | AstraZeneca AB (SE) | 2007-10-24 | — | — | EP | disclosed |
| CN-1968933-A | Pyrazole derivatives useful for the treatment of cancer | ASTRAZENECA AB (SE) | 2007-05-23 | — | — | CN | disclosed |
| WO-2007049041-A1 | 4- (3-AMINOPYRAZOLE) PYRIMIDINE DERIVATIVES FOR USE AS TYROSINE KINASE INHIBITORS IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2007-05-03 | — | — | WO | disclosed |
| CN-1905884-A | Pyrazole derivatives as inhibitors of receptor tyrosyne kinases | ASTRAZENECA AB (SE) | 2007-01-31 | — | — | CN | disclosed |
| EP-1742921-A2 | PYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER | AstraZeneca AB (SE) | 2007-01-17 | — | — | EP | disclosed |
| WO-2006087538-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2006-08-24 | — | — | WO | disclosed |
| WO-2006087530-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2006-08-24 | — | — | WO | disclosed |
| WO-2006082392-A1 | PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | WO | disclosed |
| WO-2005103010-A2 | PYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180346451-A1 | TRK INHIBITION | NGFR, NGF, NTRK1 | DYRK1A 556/4885SMN1; SMN2 1519/4885HSD17B10 4333/4885 |
| US-10738033-B2 | Trk inhibition | NGF, NGFR, NTRK2 | DYRK1A 737/4885SMN1; SMN2 1979/4885HSD17B10 4160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.